Table 5.

OS Multivariate Cox PH Regression of Significant Covariates in CRPC Patients Receiving Chemotherapy from Start of Chemotherapy.

Variable	Reference	HR		95% CI	p
Age at Diagnosis (years)					0.58
Group A <55	65 to 74	1.18	0.70-2.01		0.96
Group B 55 to 64	65 to 74	0.88	0.61-1.28		0.50
Group D ≥ 75	65 to 74	0.71	0.30-1.64		0.42
ECOG					0.08
2	0-1	1.31	0.82-2.10		0.25
≥3	0-1	2.52	1.04-6.08		0.03
PSA Doubling Time					0.003
≥ 0 and < 30 days	<0 or ≥ 60	1.86	1.21-2.86		0.005
≥ 30 and <60 days	<0 or ≥ 60	0.96	0.65-1.40		0.64
Log(ALP)	(cont.)	1.02	0.85-1.24		0.82
Log(LDH)	(cont.)	2.43	1.62-3.62		<0.0001
Hgb (g/L)					0.0002
<100	≥ 140	3.62	1.77-7.42		0.0004
100-119	≥ 140	2.07	1.09-3.96		0.03
120-139	≥ 140	1.24	0.70-2.22		0.46
Type of Chemotherapy
Docetaxel	Other	0.47	0.32-0.69		0.0001

Abbreviations: OS, overall survival; CRPC, castration resistant prostate cancer; PSA, prostate specific antigen; ECOG, Eastern Cooperative Oncology Group; ALP, alkaline phosphatase; Hgb, hemoglobin.